LUCINDA is a clinical research trial to determine whether leuprolide (Eligard, an injectable medication) can slow or prevent decline in thinking abilities and functioning in women with mild cognitive impairment (MCI) or Alzheimer’s disease who are also taking a cholinesterase inhibitor medication such as donepezil.

LUCINDA is taking place at three sites in the United States: Weill Cornell Medicine in New York, NY; University of Miami in Boca Raton, FL and University of Wisconsin–Madison, in Madison, Wisconsin.

What does the study involve?

If you are interested, a research coordinator will give you detailed information about the study. You will be asked to sign an informed consent form. There will be approximately eight study visits spread out over one year. Study procedures include tests of thinking abilities, blood tests, two MRI scans and one PET scan to measure amyloid in the brain. There will be injection of study drug (leuprolide or placebo) four times over one year.

Participation Eligibility
  • Women over age 60
  • Diagnosed with mild cognitive impairment or Alzheimer's disease
  • Taking a cholinesterase inhibitor medication such as the medication donepezil (Aricept)
  • Participants must have a study partner (friend, family member or caregiver) who can accompany them to all study visits
  • Detailed eligibility will be reviewed with the study team

View the LUCINDA flyer and brochure below: 

LUCINDA flyer.pdf

LUCINDA brochure.pdf

For more detailed information, please visit the LUCINDA clinical trial website.

Contact the study coordinator below to find out if you are eligible to enroll in the LUCINDA clinical trial.

Study Coordinator

Headshot of Maggie Chilsen
Clinical Research Coordinator II

Study leadership

craig atwood phd
Department of Medicine
Division of Geriatrics and Gerontology